While the office of the Drugs Controller General of India is still struggling to accumulate data, compensation had been paid only in 50 per cent of the clinical trial death cases so far, sources said.
Companies run till now by mostly their promoters are increasingly inducting professionals to head their teams.
Charge relates to misuse of dominant position to sell spare parts at high rates.
No ethics committee shall review and accord its approval to a clinical trial protocol without prior registration with the licensing authority, as defined in clause (b) of rule 21.
Disappointed with past experience, domestic majors even skip giving any memorandum.
Regulator mentions Wockhardt as manufacturer but firm says it only markets drug.
Company has taken preliminary tests of 1,181 candidates from state ITI.
The patent office said Pfizer's claimed patent for Sutent, a cancer drug, did not involve any inventive step.
Health & family welfare ministry's proposal seeks to restrict sale of antibiotics to check self-medication.
Prodded by patent cliff & increasing competition, it files application for foray into injectible oncology segment.
Says company yet to file audited accounts, without which it can't proceed.
Firms could lose licence if products not launched within 6 months of approval.
Executives caused loss of Rs 11 cr, according to police SIT.
An interview with Ranbaxy CEO and MD Arun Sawhney on the changes in the past four years and how the company plans to address the US concerns.
SFIO official refuses to reveal the nature of additional charges found during investigation.
Sharad Pawar says final draft will go to Cabinet before Tuesday.
Company refuses to comment, says 'matters internal to organisation'
Another cap for imported insulin; domestic manufacturers cry foul.
FinMin had objected and wanted existing cost-plus method retained.
CCI to examine competition part of deals, RBI prudential aspects.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances